SEC Form 4 · accession 0001003642-16-000030
Impax Laboratories, LLC · IPXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas Boothe
Officer — President, Generics Division
Period of report
Aug 30, 2016
Accepted (ET)
Aug 31, 2016 · 2:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001003642
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 30, 2016 | A | 62,600 | $0.00 | A | 62,600 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $24.42 | Aug 30, 2016 | A | 50,500 | A | — | Aug 30, 2026 | Common Stock | 50,500 | 50,500 | D |
Explanation of responses
- F1The option vests in four equal annual installments beginning on August 1, 2017, which is the first anniversary of the effective date of Mr. Boothe's appointment as the Company's President, Generics Division.
Remarks
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.